(Q45049153)

8 December 2017

Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms (English)

1 reference

8 December 2017

0 references

0 references

0 references

1 reference

Joachim Klosterkötter

7

object named as

Joachim Klosterkötter

1 reference

8 December 2017

Andrea Giuffrida

1

1 reference

8 December 2017

F Markus Leweke

2

1 reference

8 December 2017

Christoph W Gerth

3

1 reference

8 December 2017

Daniela Schreiber

4

1 reference

8 December 2017

Dagmar Koethe

5

1 reference

8 December 2017

Johannes Faulhaber

6

1 reference

8 December 2017

Daniele Piomelli

8

1 reference

8 December 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

8 December 2017

Neuropsychopharmacology

1 reference

8 December 2017

29

1 reference

8 December 2017

11

1 reference

8 December 2017

2108-2114

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300558

8 December 2017

0 references

cites work

Increased baseline occupancy of D2 receptors by dopamine in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

CANNABIS AND SCHIZOPHRENIA A Longitudinal Study of Swedish Conscripts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Control of pain initiation by endogenous cannabinoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Endocannabinoid signalling in the blood of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Formation and inactivation of endogenous cannabinoid anandamide in central neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Dopamine activation of endogenous cannabinoid signaling in dorsal striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Cannabinoid receptor localization in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Substance use disorder and the early course of illness in schizophrenia and affective psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Localization of cannabinoid receptor mRNA in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

The role of serotonin in antipsychotic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

The molecular logic of endocannabinoid signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

An anorexic lipid mediator regulated by feeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Reduced binocular depth inversion in regular cannabis users

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Cannabis induced dopamine release: an in-vivo SPECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

7 January 2021

Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

7 January 2021

Elevated endogenous cannabinoids in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

7 January 2021

Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

7 January 2021

Cannabis abuse and the course of recent-onset schizophrenic disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300558

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1300558

1 reference

Dimensions Publication ID

8 December 2017

0 references

1 reference